Same Indication

Cianidanol vs Durvalumab

Cianidanol vs Durvalumab: Overview

This comparison examines the pharmacological differences between Cianidanol and Durvalumab.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Pharmacokinetics

Half-life: Durvalumab β€” 17 days.

Chemical Properties

Type: Cianidanol β€” Small molecule; Durvalumab β€” Antibody.